Healthcare Regulation (HIPAA)

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

A new partnership in regenerative medicine aims to capitalize on Florida's progressive laws. But does it signal a new era of healthspan or a risky medical frontier?

A new grand jury report exposes a perfect storm in SF jails: surging inmates with severe health needs, crumbling buildings, and burned-out staff.

Krisp launches Voice Translation v3 and a developer API, bringing its 96% accurate, battle-tested engine to high-stakes industries and innovators alike.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

ResVita Bio's new board member signals a major shift. We explore how visionary leadership and living medicine are converging to tackle long-neglected diseases.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

EVERSANA poaches Takeda's Jen Norton to lead a new tech-first unit, signaling a high-stakes bid to dominate the complex life sciences access market.

With Bill S-228, Canada is criminalizing forced sterilization. It’s more than a new law; it’s a reckoning with a dark history and a test of reconciliation.

Dr. Farzad Mostashari’s recent accolade is more than an award; it’s a validation of a strategic model proving that realigning incentives can save billions.

Conexeu Sciences hits a key manufacturing milestone for its innovative wound-healing gel, but the path to FDA clearance and a crowded market remains a challenge.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.

Metropolitan Dermatology is the first in NJ to adopt Nevisense®, an AI-backed scanner for melanoma. Is this tech a true game-changer or one move in a complex market?

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

Ottawa's first national eye care strategy isn't just about health. It's a calculated investment in economic resilience and systemic stability for an aging nation.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

With key regulatory decisions pending in Canada and the US, DIAGNOS's CARA AI platform is set to unlock a multi-billion dollar market for early eye disease detection.

A new lawsuit alleges a Dallas nightclub's negligent security policy allowed a patron to bypass checks for a fee, leading to a security guard's murder.